Celltrion gains Australian approval for three biosimilars in ophthalmology and bone disease Celltrion secures TGA endorsement ...

As biotech investors know, companies in the industry can sometimes earn significant returns in relatively short periods, like ...

As Fierce Pharma points out, patent expirations are a routine occurrence in the pharmaceutical world, but 2025 stands out for ...

South Korea’s pharmaceutical giant Celltrion said Thursday it has received regulatory approvals for three biosimilars in ...

One catalyst could lead to major gains for Regeneron. It is in a legal battle with Amgen over the legality of the latter's Eylea biosimilar. If Regeneron wins the case, its shares will rocket.

Amgen has chalked up a victory in a patent infringement lawsuit with Regeneron over blockbuster ophthalmic drug Eylea and decided to launch its biosimilar in the US – even though the legal ...

Biogen will retain its commercial rights to the biosimilars already brought to market, as well as copycat version of Bayer's age-related macular degeneration blockbuster Eylea (aflibercept ...